Epidermal graft in stable vitiligo

Outcome of suction blistering epidermal graft by means of a new fraise for preparation of recipient site in depigmented lesions

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT138802251906N1

Enrollment

Unknown

Registered

2011-11-19

Start date

2006-10-10

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vitiligo and other depigmented lesions. Vitiligo

Interventions

suction blistering epidermal graft by means of a new dental lab finishing carbide bur for preparation of the recipient site in depigmented lesions. There was not control group..

Treatment - Devices

suction blistering epidermal graft by means of a new dental lab finishing carbide bur for preparation of the recipient site in depigmented lesions. There was not control group.

Eligibility

Sex/Gender

All

Age

16 Years to 29 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: depigmented lesions unresponsive to medications and phototherapy; all patients had stable disease for more than 1 year and there was not any history of a positive Kobner phenomenon. Exclusion criteria: unstable or active vitiligo; positve Kobner phenomenon; age under 12 years old and pregnancy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Repigmentation rate. Timepoint: Every week in the first month and once a month for the following 6-8 months. Method of measurement: The repigmentation rate of lesions was classified as excellent (more than 75% repigmentation), good (50-75% repigmentation), moderate (25-50% repigmentation) and poor (less than 25% repigmentation).	—

Secondary

Measure	Time frame
Perigraft halo. Timepoint: All patients were visited every week in the first month and once a month for the following 6-8 months. Method of measurement: clinical observation.;Scar and Keloid. Timepoint: All patients were visited every week in the first month and once a month for the following 6-8 months. Method of measurement: clinical observation.;Kobner phenomen. Timepoint: All patients were visited every week in the first month and once a month for the following 6-8 months. Method of measurement: clinical observation.;Color mismatch. Timepoint: All patients were visited every week in the first month and once a month for the following 6-8 months. Method of measurement: clinical observation.;Infection. Timepoint: All patients were visited every week in the first month and once a month for the following 6-8 months. Method of measurement: clinical observation and Labratory assesment.	—

Measure

Time frame

Perigraft halo. Timepoint: All patients were visited every week in the first month and once a month for the following 6-8 months. Method of measurement: clinical observation.;Scar and Keloid. Timepoint: All patients were visited every week in the first month and once a month for the following 6-8 months. Method of measurement: clinical observation.;Kobner phenomen. Timepoint: All patients were visited every week in the first month and once a month for the following 6-8 months. Method of measurement: clinical observation.;Color mismatch. Timepoint: All patients were visited every week in the first month and once a month for the following 6-8 months. Method of measurement: clinical observation.;Infection. Timepoint: All patients were visited every week in the first month and once a month for the following 6-8 months. Method of measurement: clinical observation and Labratory assesment.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAli Ebrahimi

Kermanshah University of Medical Sciences

aebrahimi@kums.ac.ir+98 83 1835 9054

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026